2017 GUIDELINES FOR
DRUGS AND
MEDICATIONS

800.633.2472
LAST REVISED NOVEMBER 2016
The USEF Equine Drugs and Medications Rules are driven by a mission to protect equine welfare and to maintain a balance of competition among USEF’s 29 unique breeds and disciplines, while simultaneously recognizing and accommodating the varied differentiations required of each. The common thread that binds all of equestrian sport is a dedication and commitment to the health, welfare and safety of the equine athlete, which must take precedence over all other aspects of training, competing and showing.

The USEF recognizes that horses under its jurisdictions might experience competition stressors which could result in situations where legitimate, therapeutic treatment is indicated near the time of competition. Provisions of the Equine Drugs and Medications Rules address these circumstances; however, the USEF and its members mutually acknowledge that these practices should never be a substitute for good horsemanship. Similarly, there are some medications that may be used responsibly for treatment of injury or illness in equine athletes outside of competition, but these same medications should never be found in a horse at the time of competition.
The Federation rules have, over time, been primarily focused upon detection of prohibited substances and have provided guidelines for the administra­
tion of permitted therapeutic medications for competition horses. The concept of legislating prohibited practices was introduced in the 1970’s by the USDA in the Horse Protection Act and was focused primarily upon soring techniques which were (and continue to be) prevalent in certain segments of the Tennessee Walking Horse breed.

Today’s advances in medicine, cutting-edge therapies, and nutritional science afford practitioners and equestrians alike numerous opportunities to aid and assist the equine athlete in the competition environment. With a view to the landscape of these advancements coupled with analysis of the current equestrian competition environment, there is a need to closely examine these advancements for the purpose of providing guidelines for owners, trainers, and treating veterinarians regarding appropriate use with horses in competition.

“12-HOUR RULE:”
The United States Equestrian Federation recently reviewed relevant con­cerns to the welfare of our equine athletes that involve specific practices. Serving as a basis for this review was the white paper released by the American Association of Equine Practitioners (AAEP) in December 2011 entitled Clinical Guidelines for the Treatment of Non-Racing Performance Horses. “AAEP White Paper.” Review of “same day” medication protocol in the “AAEP White Paper” led to the conclusion that there is no basis upon which it is necessary for equine athletes to be injected within 12 hours of competing. The USEF Veterinary Committee has subsequently identified three specific scenarios where injection might be appropriate that have been written into the “12-Hour Rule.” In racing, no medications are permitted to be administered for 24-48 hours (depending upon the racing jurisdiction), prior to a race. The USEF Equine Drugs & Medications Program is underpinned by a belief that judicious use of certain therapeutic substances may be appropriate for equine athletes in competition, the new “12-Hour Rule” remains consistent with this philosophy which continues to guide the Program.

WITHDRAWAL FOLLOWING INTRA-ARTICULAR INJECTIONS
As referenced above, the AAEP produced a white paper for the “Clinical Guidelines for the Treatment of Non-Racing Performance Horses” in 2011. This document was intended to provide its members and the equine industry an understanding of appropriate care that should be considered when treating this subset of the equine population. It is recognized that there are differences between the various breeds and disciplines and their specific needs.

Regarding the use of intra-articular (IA) injections, this document includes the following statement: “AAEP recognizes that the judicious use of intra-articular medications with a valid veterinarian-patient relationship is appropriate treatment and can benefit a horse’s health and wellbeing. AAEP defines this relationship to be a clinical or lameness examination with appropriate diagnostic tests prior to initiation of a therapeutic plan. Clinicians treating performance horses in the competitive environment are
encouraged to develop treatment regimens, particularly with reference to the use of IA corticosteroids, which allow adequate evaluation of the horse’s response to treatment prior to competition.”

There is a growing concern in the field of equine practice that intra-articular injections are less frequently used to treat a specific diagnosis and are more commonly used as a type of “maintenance” therapy. Frequently, Medication Report Forms are received in the Equine Drugs and Medications Program office documenting intra-articular injections of yearlings within 24-48 hours of competing in the in-hand classes. These injections are not being performed as part of a specific treatment plan for a specific diagnosis. Additionally, the timing does not provide for a sufficient interval to allow evaluation of the response to treatment prior to returning to competition.

Intra-articular injections are intended to be therapeutic, but are not necessarily benign procedures. Not all substances being injected are considered to be protective of the articular cartilage and some corticosteroids are even thought to be damaging to articular cartilage. Due to these concerns, racing authorities around the world have begun to address the issue of intra-articular injections. In December of 2012, the Racing Medication and Testing Consortium (RMTC) approved a prohibition on intra-articular use of corticosteroids within seven days of race.

The USEF Veterinary Committee proposed in 2013 that a withdrawal time following intra-articular injections be implemented. The Federation’s Board approved the rule change with an effective date of 12/1/14.

### WITHDRAWAL FROM SHOCKWAVE THERAPY

Currently, most racing jurisdictions prohibit the use of shockwave within the 5-7 days preceding competition. The FEI prohibits the use of shockwave within the FEI compound and within the 5 days preceding competition.

While shockwave is a valuable tool to be used in the treatment of soft tissue injuries in horses, it can also be misused if solely used to provide analgesia close to competition and/or without a specific diagnosis.

Concerns in racing focus around the analgesic effect provided by extracorporeal shockwave therapy, and its potential to place a horse at risk for catastrophic failure and further injury or death. The USEF Veterinary Committee has recommended a 3 day withdrawal from competition following extracorporeal shockwave therapy. The deviation from a 5-7 day prohibition as implemented by other governing bodies is due to the acknowledgement by the USEF Veterinary Committee that horses competing at USEF competitions are at less risk for catastrophic failure. However, the Veterinary Committee agrees that no horse should be exposed to shockwave and then compete within 3 days based on current science and expert opinion.

Shockwave Therapy may be administered by a licensed veterinarian within the 3 day prohibited period, but no closer than 12 hours prior to competing, and is limited to application to the back and dorsal pelvis areas. No Shockwave Therapy is permitted within the 12 hours prior to competing.

### GR 414 PROHIBITED PRACTICES

1. No injectable substances may be administered to any horse or pony within 12 hours prior to competing, with the following three exceptions subject to paragraph 2:
a. Therapeutic fluids, which amount must consist of a minimum of 10L of polyionic fluids; and which must be used in accordance with the manufacturer's recommendations and guidelines. The fluids must not be supplemented with concentrated electrolytes, such as magnesium.

b. Antibiotics. Procaine penicillin G is prohibited under this exception.

c. Dexamethasone. This is permitted only for the treatment of acute urticaria (hives). The dose must not exceed 0.5 mg per 100lb (5.0 mg for 1000lb horse) if administered more than 6 hours and less than 12 hours prior to entering the competition ring, and must not exceed 1.0 mg per 100lb (10.0 mg for 1000lb horse) within any 24 hour period.

2. These three exceptions are permitted only when (i) the substance is administered by a licensed veterinarian and no less than six hours prior to competing; and (ii) the “Trainer” as defined under General Rule 404 properly files, or causes to be properly filed, an Equine Drugs and Medications Report Form with the Steward/Technical Delegate or competition office representative within one hour after the administration of the substance or one hour after the Steward/Technical Delegate or competition office representative returns to duty if the administration occurs at a time outside competition hours. The Steward/Technical Delegate or competition office representative shall sign and record the time of receipt on the Equine Drugs and Medications Report Form.

3. No horse may be injected with any substance, forbidden or permitted, into an intra-synovial space (joint, tendon sheath, or bursa) within the 4 days preceding competition. No horse less than two years of age may be treated with intrasynovial injections within the 30 days preceding competition.

4. Shockwave Therapy may only be administered by or on the order of a licensed veterinarian. If sedation is required for Shockwave Therapy, only sedation performed by a licensed veterinarian and administered at the same time as the Shockwave Therapy will be considered therapeutic and GR411 will apply. No sedation associated with Shockwave Therapy will be considered therapeutic if administered within 24 hours prior to competition. No horse may be treated with Shockwave Therapy within the 3 days preceding competition with the following exception:

   a. Shockwave Therapy may be administered by a licensed veterinarian within the 3 day prohibited period, but no closer than 12 hours prior to competing, and is limited to application to the back and dorsal pelvis areas. No Shockwave Therapy is permitted within the 12 hours prior to competing. This exception is permitted only when the “Trainer” as defined under General Rule 404 properly files, or causes to be properly filed, an Equine Drugs and Medications Report Form with the Steward/Technical Delegate or competition office representative within one hour after the administration of Shockwave Therapy or one hour after the Steward/Technical Delegate or competition office representative returns to duty if the administration occurs at a time outside competition hours. The Steward/Technical Delegate or competition office representative shall sign and record the time of receipt on the Equine Drugs and Medications Report Form. (Effective 12/1/14)
ACCOUNTABILITY FOR USEF DRUGS & MEDICATIONS VIOLATIONS

The USEF Board of Directors recently approved a rule change which expands the range of responsible parties for violations of the USEF’s Equine Drugs and Medications rules. Beginning on December 1, 2015, the rule includes additional categories of individuals who are responsible and accountable parties which are defined as Persons Responsible and Support Personnel.

The Trainer will continue to be held accountable as a responsible party, however, in addition to the Trainer, Persons Responsible include the individual who rides, vaults or drives the horse and/or pony during competition and/or the Owner, and other Support Personnel. Support Personnel includes, but is not limited to: grooms, handlers, longeurs, and veterinarians if they are present at the competition or have made a relevant decision about the horse and/or pony.

Though under the new rule, a minor exhibitor might fall under the Persons Responsible; there must be substantial evidence to support holding a minor accountable.

Neither the Trainer nor any Persons Responsible, including Support Personnel, may be relieved from his responsibility under the USEF’s Equine Drugs and Medications Rules due to a lack or insufficiency of stable security. Therefore, the insufficiency of stable security or lack of security will not be an acceptable defense to any drug positive or medication overage in a horse.

The USEF is considering additional changes to GR404 due to feedback it has received since the rule was passed.
EXAMPLES OF FORBIDDEN SUBSTANCES UNDER USEF EQUINE DRUGS AND MEDICATIONS RULES

acepromazine  | chlorbutanol  | ethyl alcohol
acetophenazine | chlorothiazide | etidocaine
acetylpromazine | chlorpheniramine | etodolac
albuterol | chlorpromazine | etomidate
alfentanil | chlorprothixene | etorphine
alprazolam | citrize | eugenol
aminophylline | clenbuterol | fenfluramine
amitriptyline | clozapine | fenspiride
amphetamines | cocaine | fentanyl
antihistamines | codeine | fentiazac
apomorphine | comfrey | fluanisone
arsenic | cyclobenzaprime | fluoxetine
atropine | cyproheptadine | fluphenazine
azaperone | dantrolene | furosemide
barbiturates | demethylpyrilamine | GABA
belladonna | detomidine | gabapentin
benperidol | devil's claw | glycerol guaiacolate
benzocaine | dextromethorphan | glycopyrrolate
benzodiazepines | dextromoramide | guaifenesin
beta blockers | dezocine | guanabenz acetate
bethanechol chloride | diazepam | haloperidol
boldenone | digoxin | homatropine
bromperidol | diphenhydramine | hops
bumetanide | dipremorphine | hydrochlorothiazide
bupivacaine | dipyrone | hydrocodone
buprenorphine | doxapram | hydromorphone
buspirone | doxepin | hydroxyzine
butorphanol | droperidol | imipramine
caffeine | dyphylline | ipratropium
camphor | ephedrine | kava kava
capsaicin | epinephrine | ketamine
carfentanil | epoetin alfa | ketorolac
carisoprodol | erythropoetin | laurel
carprofen | etamiphylne | lavender
chamomile | ethacrynic acid | levallorphan
chloral hydrate | ethchlorvynol | levorphanol
leopard's bane  
licofane  
lithium  
lorazepam  
LSD  
mabuterol  
mazindol  
meclizine  
medetomidine  
meperidine  
mepenzolate bromide  
mephenertamine  
mepivacaine  
mepyrcale  
methadone  
methamphetamine  
methaqualone  
methyldopa  
methylphenidate  
metyopimadine  
milenperone  
molindone  
moperone  
morphine  
nalbuphine  
nalmefene  
naloxone  
nandrolone  
nefopam  
night shade  
nikethamide  
nitrazepam  
nitroglycerin  
opiates  
orpheadrine citrate  
oxymetazoline  
oxymorphone  
paroxetine  
pertxozine  
pentoxifylline  
pergolide mesylate  
phencyclidine  
phenibut  
phenobarbital  
phentermine  
phenylephrine  
phenylpropanolamine  
phenytoin  
piperacetazone  
pienperone  
pramoxine  
pzepam  
prethcamide  
prilocaine  
procaine  
procaine penicillin  
procaterol  
prochlorperazine  
procyclidine  
promazine  
promethazine  
propofol  
propriomazine  
propionylpromazine  
propoxphene  
propranolol  
pseudoephedrine  
pyrilamine  
ractopamine  
ratowalia  
red poppy  
reserpine  
risperidone  
romifidine  
salmeterol  
scolopamine  
serratiline  
skullcap  
sodium cacodylate  
siperone  
stanozolol  
strychnine  
sufentanil  
sumatriptan  
terbutaline sulfate  
terfenadine  
testosterone  
tetracline  
THC  
theobromine  
theophyline  
tolmetin  
tramadol  
trazodone  
trichlorethiazide  
trifluperidol  
triheixyphenidyl  
tripleaneamine  
tropicamide  
valerian  
vervain  
xylose  
xylocaine  
zilpaterol  
zolpidem
### RESTRICTED MEDICATION DOSE AND TIME RECOMMENDATIONS

<table>
<thead>
<tr>
<th>MEDICATION GENERIC NAME</th>
<th>MEDICATION TRADE NAME</th>
<th>MAX DOSAGE PER POUND OF BODY WEIGHT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dexamethasone</td>
<td>Azium®</td>
<td>1.0 mg/100Lb (10 mg/1000Lb) or 0.5 mg/100Lb (5.0 mg/1000Lb)</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>Surpass®</td>
<td>5 inch ribbon, ½ inch thick, one site</td>
</tr>
<tr>
<td>Firocoxib</td>
<td>Equioxx®</td>
<td>0.1 mg/kg (0.0455 mg/Lb) (45.5 mg/1000Lb)</td>
</tr>
<tr>
<td>Phenylbutazone (“bute”)</td>
<td>Butazolidin®</td>
<td>2.0 mg/Lb (2.0 grams/1000Lb) or 1.0 mg/Lb (1.0 grams/1000Lb)</td>
</tr>
<tr>
<td>Flunixin meglumine</td>
<td>Banamine®</td>
<td>0.5 mg/Lb (500 mg/1000Lb)</td>
</tr>
<tr>
<td>Ketoprofen</td>
<td>Ketofen®</td>
<td>1.0 mg/Lb (1.0 grams/1000Lb)</td>
</tr>
<tr>
<td>Meclofenamic acid</td>
<td>Arquel®</td>
<td>0.5 mg/Lb (500 mg/1000Lb)</td>
</tr>
<tr>
<td>Naproxen</td>
<td>Naprosyn®</td>
<td>4.0 mg/Lb (4.0 grams/1000Lb)</td>
</tr>
<tr>
<td>Methocarbamol</td>
<td>Robaxin®</td>
<td>5.0 mg/Lb (5.0 grams/1000Lb)</td>
</tr>
</tbody>
</table>

**PLEASE NOTE**

Beginning 12/1/2011, do not administer more than one permitted NSAID at a time. NSAID Disclosure forms are not accepted following this date.

Whenever two NSAIDs are administered, one must be discontinued at least three (3) days prior to competing.

Whenever any NSAID is administered that does not appear on the permitted list (GR 410.4), it must not have been administered during the seven days prior to competing.

The maximum treatment time for any of the above permitted medications is five days, with the exceptions of diclofenac and firocoxib. Diclofenac can...
be administered for 10 successive days, and firocoxib can be administered for 14 successive days.

Caution is urged when using compounded medications with varying administration routes not specified above. Only the above administration routes with non-compounded medications have been evaluated for the dose and time recommendations.

This chart is for quick reference only and should not be used in place of the detailed guidelines on the following pages.

<table>
<thead>
<tr>
<th>LATEST ADMINISTRATION HOUR PRIOR TO COMPETITION</th>
<th>ADMINISTRATION METHOD</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;12 hours</td>
<td>Oral, IV, IM</td>
</tr>
<tr>
<td>&gt;*6 hours</td>
<td>*IV</td>
</tr>
<tr>
<td>&gt;12 hours</td>
<td>Topical, 2 doses each day 12 hours apart</td>
</tr>
<tr>
<td>&gt;12 hours</td>
<td>Oral</td>
</tr>
<tr>
<td>&gt;12 hours</td>
<td>Oral, IV</td>
</tr>
<tr>
<td>AM &amp; PM feed</td>
<td>Oral, 2 doses each day, 12 hours apart</td>
</tr>
<tr>
<td>&gt;12 hours</td>
<td>Oral, IV</td>
</tr>
<tr>
<td>&gt;12 hours</td>
<td>IV</td>
</tr>
<tr>
<td></td>
<td>Oral, 2 doses each day, 12 hours apart</td>
</tr>
<tr>
<td>&gt;12 hours</td>
<td>Oral</td>
</tr>
<tr>
<td>&gt;12 hours</td>
<td>Oral, IV</td>
</tr>
</tbody>
</table>

* MUST BE ADMINISTERED BY A VETERINARIAN AND A MEDICATION REPORT FORM FILED.
PRACTICAL ADVICE REGARDING THE 2017 EQUINE DRUGS AND MEDICATIONS RULE

INTRODUCTION
It is regrettable and true that many violations of the Equine Drugs and Medications Rule result from the failure of exhibitors, owners, trainers, and their veterinarians to familiarize themselves with all new and existing regulations required to be in compliance. This article is written to help you avoid inadvertent violations.

The text that follows includes advice about understanding the Equine Drugs and Medications Rule and applying it in practical situations. Its purpose is to help accommodate legitimate therapy in compliance with the requirements of the rules. This practical advice in no way takes precedence over the wording of the Equine Drugs and Medications Rule itself, which is printed in its entirety in the Federation’s Rule Book and posted on its website at www.usef.org, and which is REQUIRED READING for trainers, owners, exhibitors, and their veterinarians.

DIFFERENT RULES FOR DIFFERENT GROUPS
Most breeds and disciplines that compete under USEF Rules are subject to the Therapeutic Substance Provisions (GR410–412). The Endurance Discipline is subject to the Prohibited Substance Provisions (GR 409). Other breeds and disciplines may choose this option, if they wish.

GR409 has changed to the Prohibited Substances Provisions and applies to all FEI recognized disciplines. A review of approved rule changes to GR409 on page 30 of these guidelines and the applicable FEI Equine Anti-Doping Rules is suggested.

FEI recognized events are subject to the FEI Veterinary Regulations and the FEI Equine Anti-Doping and Controlled Medication Regulations. The FEI maintains a Prohibited Substance Rule, which includes reporting requirements for the treatment of illness and injury. Selection trials for FEI recognized international events and other events may be subject to a Prohibited Substance rule as specified in the Selection Procedures.

THE THERAPEUTIC SUBSTANCE PROVISIONS
TREATMENT OF ILLNESS OR INJURY WITH A FORBIDDEN SUBSTANCE
Any product is forbidden if it contains an ingredient that is a forbidden substance, or is a drug which might affect the performance of a horse and/or pony as a stimulant, depressant, tranquilizer, analgesic, local anesthetic, psychotropic (mood and/or behavior altering) substance, or might interfere with drug testing procedures.

TRAINERS, OWNERS, EXHIBITORS, AND THEIR VETERINARIANS ARE CAUTIONED AGAINST THE USE OF MEDICINAL PREPARATIONS, TONICS, PASTES, POWDERS AND PRODUCTS OF ANY KIND, INCLUDING THOSE USED TOPICALLY, THE INGREDIENTS AND QUANTITATIVE ANALYSIS OF WHICH ARE NOT SPECIFICALLY KNOWN, AS THEY MIGHT CONTAIN A FORBIDDEN SUBSTANCE. THIS IS ESPECIALLY TRUE OF THOSE CONTAINING PLANT INGREDIENTS.
After a horse or pony has been administered any product containing a forbidden substance, and before the animal is returned to competition, the following requirements must be met:

1. The product must be used for a legitimate therapeutic purpose only. The rule accommodates the use of a forbidden substance for the diagnosis or treatment of illness or injury only. If a forbidden substance is administered for any other purpose, e.g., clipping, shipping, training, the animal must be kept out of competition until the forbidden substance is no longer detectable in the animal's blood or urine sample. This can be a long time (see HOW LONG DRUGS REMAIN DETECTABLE on page 17).

2. After a horse or pony has been administered for a therapeutic purpose any product containing a forbidden substance, the animal must be withdrawn from competition for at least 24 hours. This is a uniform requirement for all therapeutic forbidden substances and there are no exceptions.

3. A Medication Report Form must be filed documenting the therapeutic use of a forbidden substance. A Medication Report Form should be obtained from the steward or technical delegate, filled out completely and turned in to the steward or technical delegate, or filed online (see p.19). All this must be done within one hour after administration or one hour after the Steward/Technical Delegate or Designated Competition Office Representative returns to duty if administration is at a time other than during competition hours.

How long after treatment of any illness or injury is it necessary to file a Medication Report Form? It is necessary for as long as the drug might remain detectable in a horse's or pony's blood or urine (see HOW LONG DRUGS REMAIN DETECTABLE on page 17).

CAUTION AGAINST THE USE OF HERBAL/NATURAL PRODUCTS

Persons administering a so-called herbal or natural product to a horse or pony to affect its performance, having been comforted by claims that the plant origin of its ingredients cause it to be permitted by the rules as well as undetectable by drug tests, might have been misled.

The use of so-called herbal and natural products in a horse or pony might result in a positive drug test, i.e., a finding of a forbidden substance, contrary to claims by those who manufacture and/or market such products for profit. The plant origin of any ingredient does not preclude its containing a pharmacologically potent and readily detectable forbidden substance, e.g., cocaine, heroin and marijuana all come from plants.

Although the use of some of these products may not have resulted in positive drug tests in the past, this may change as the USEF Equine Drug Testing and Research Laboratory incorporates new methods into its battery of screening tests, a deliberate and ongoing process.

For the above reasons, the Federation cautions most strongly against the use of so-called herbal and natural products, the ingredients and properties of which are not known. In this regard trainers should be most skeptical about any claims by manufacturers or others that their preparation is “legal” or permissible for use at competitions recognized by the Federation or the FEI. Trainers should be aware that ingredients labeling for such preparations...
is often not complete or accurate. Especially suspect are preparations that claim to calm or relax while at the same time claiming to contain no forbidden or prohibited substances. Just some of the hundreds and perhaps thousands of examples of herbal/natural or plant ingredients that would cause a product to be classified as forbidden are valerian, kava kava, passionflower, skullcap, chamomile, vervain, leopard's bane, night shade, capsaicin, comfrey, devil's claw, hops, laurel, lavender, red poppy and rawuolfia.

TRAINERS, OWNERS, EXHIBITORS, AND THEIR VETERINARIANS ARE CAUTIONED AGAINST THE USE OF MEDICINAL PREPARATIONS, TONICS, PASTES, POWDERS AND PRODUCTS OF ANY KIND, INCLUDING THOSE USED TOPICALLY, THE INGREDIENTS AND QUANTITATIVE ANALYSIS OF WHICH ARE NOT SPECIFICALLY KNOWN, AS THEY MIGHT CONTAIN A FORBIDDEN SUBSTANCE. THIS IS ESPECIALLY TRUE OF THOSE CONTAINING PLANT INGREDIENTS.

“APPROVED” OR “ENDORSED” PRODUCTS

It is a longstanding policy that USEF does not approve, endorse, or sanction herbal, natural or medicinal products of any kind. Trainers, owners and exhibitors are advised to disregard any such representations, statements or testimonials made by the manufacturer. Any individual who becomes aware of a product, the label of which contains a statement that it is “USEF Approved” or “USEF Endorsed,” etc., should forward a copy of the label to the office of the Equine Drugs and Medications Program.

GUIDELINES FOR THE THERAPEUTIC USE OF DEXAMETHASONE AND OTHER CORTICOSTEROIDS

USEF Rules provide for the use of corticosteroids such as dexamethasone in horses only for a therapeutic purpose, i.e., for the treatment of existing inflammatory conditions related to illness or injury. The rules do not permit the use of corticosteroids for a non-therapeutic purpose, i.e., to affect the mood or enhance the performance of the horse.

The rules establish a quantitative restriction for dexamethasone, i.e., a maximum permitted plasma concentration (fluid portion in blood). Due to the adoption of the 12-Hour Rule prohibiting injections from being administered within the 12 hours prior to competing, a new plasma level of 0.5 nanograms, per milliliter at the time of competition has been determined. In order to help trainers, owners, and their veterinarians achieve compliance with this new rule in connection with the therapeutic use of dexamethasone, it should be administered in accordance with the guidelines below. Whenever dexamethasone is administered, the dose should be accurately calculated according the actual weight of the animal.

Alternative Number 1

(1.0 mg or less per 100 pounds IV or IM at 12 or MORE hours before competition)

Each 24 hours, not more than 1.0 milligrams of dexamethasone injectable solution per 100 pounds of body weight should be administered intravenously or intramuscularly. For a 1000 pound animal, the maximum daily intravenous or intramuscular dose of dexamethasone injectable solution is 10.0 milligrams, which equals 2.5 milliliters of the injectable solution (4.0
milligrams per milliliter). No part of this dose should be administered during the 12 hours prior to competing. Dexamethasone should not be administered for more than five successive days.

Alternative Number 2

(0.5 mg or less per 100 pounds IV at 6 or more hours before competition)

Each 24 hours, not more than 0.5 milligrams of dexamethasone injectable solution per 100 pounds of body weight should be administered intravenously, preferably less. For a 1000 pound animal, the maximum daily intravenous dose of dexamethasone injectable solution is 5.0 milligrams, which equals 1.25 milliliters of the injectable solution (4.0 milligrams per milliliter). No part of this dose should be administered during the 6 hours prior to competing. Dexamethasone should not be administered for more than five successive days. **IMPORTANT:** This alternative dose for dexamethasone can only be administered by a licensed veterinarian for the treatment of hives (urticarial). A Medication Report Form must be filed consistent with GR411. The filing of a Medication Report Form is required to document compliance with the new 12-Hour Rule prohibiting injections in the 12 hour period prior to competing.

Alternative Number 3

(1.0 mg or less per 100 pounds orally at 12 or more hours before competition)

Each 24 hours, not more than 1.0 milligrams of dexamethasone powder per 100 pounds of body weight should be administered orally, preferably less. For a 1000 pound animal, the maximum daily oral dose of dexamethasone powder is 10.0 milligrams, which equals one packet of dexamethasone powder (10.0 milligrams per packet). No part of this dose should be administered during the 12 hours prior to competing. Any medicated feed should be either consumed or removed at least 12 hours prior to competing. Dexamethasone should not be administered for more than five successive days.

Corticosteroids other than dexamethasone, e.g., prednisone, prednisolone, Solu-Delta-Cortef®, and others, are classified as forbidden substances, and use of these drugs is subject to the requirements of GR411. This means these drugs are to be used only for a therapeutic purpose, i.e., for the treatment of existing inflammatory conditions related to illness or injury; they are to be administered at a time not closer than 24 hours prior to competing; and a Medication Report Form must be filed in a timely fashion in connection with any administration performed by any route during the seven days prior to competing. When using the corticosteroid methylprednisolone (Depo-Medrol®), the recommendation is to file a Medication Report Form if competing within 14 days of administration. When using the corticosteroid isoﬂupredone (Predef2X®) in injecting the sacro-ilial (SI) joint, the recommendation is to file a Medication Report Form if competing within 28 days of administration.

Trainers, owners, and their veterinarians are cautioned against the use of dexamethasone isonicotinate injectable solution, because administration studies have shown it is not eliminated from the plasma as quickly as dexamethasone injectable solution. Therefore, the use of dexamethasone isonicotinate injectable might result in an inadvertent overage, i.e., a plasma
concentration of dexamethasone in excess of the maximum permitted plasma concentration of 0.5 nanograms per milliliter at the time of competition.

Whenever dexamethasone injectable solution or dexamethasone oral powder is administered in a manner that might cause the plasma concentration to exceed the maximum permitted by the rule, the trainer and owner should withdraw the animal from competition for a sufficient amount of time such that the plasma concentration of dexamethasone returns to acceptable limits prior to competition.

Products or preparations that contain dexamethasone or another corticosteroid as an active ingredient (e.g. a Naquasone® bolus contains 5.0 milligrams of dexamethasone), should be used in accordance with the guidelines listed, taking into account the actual weight of the animal. Some products or preparations containing dexamethasone may also contain a diuretic (e.g. hydrochlorothiazide or chlorothiazide) which is considered a forbidden substance; a Medication Report Form must be filed to document compliance with GR411 when using these products.

GUIDELINES FOR THE THERAPEUTIC USE OF A NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) AND METHOCARBAMOL

Effective December 1, 2011, USEF GR410 permits the use in horses and ponies of not more than one nonsteroidal anti-inflammatory drug (NSAID) at a time (of those permitted to be used), imposes quantitative restrictions on those permitted, and forbids the use of any other NSAID. The information in this article will help owners, trainers, and their veterinarians stay in compliance with these rules, as they treat their horses and ponies with NSAIDs.

NSAIDs are to be administered to a horse or pony only for a therapeutic purpose. The following are permitted to be used (these are the generic names, not brand names): diclofenac liposomal cream, firocoxib, phenylbutazone, flunixin meglumine, ketoprofen, meclofenamic acid, and naproxen. When administered, the NSAIDs above should be administered in accordance with the guidelines below, and no other NSAIDs are to be administered.

1. Whenever diclofenac liposomal cream is administered, not more than 73 mg should be administered, to not more than one affected site, each 12 hours (i.e., not more that 146 mg per 24 hour period). This 73 mg dose equals a 5-inch ribbon of cream not greater than ½ inch in width, which should be rubbed thoroughly into the hair over the joint or affected site using gloved hands. Administration of diclofenac cream should be discontinued at least 12 hours prior to competing. Do not apply diclofenac cream in combination with any other topical preparations including DMSO, nitrofurazone, or liniments, and do not use on an open wound. Diclofenac cream should not be administered for more than 10 successive days.

2. Whenever firocoxib is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 0.0455 mg per pound of body weight should be administered. For a 1000 pound animal, the maximum daily dose is 45.5 mg, which equals four markings on the dosing syringe that contains the medication and is supplied by the manufacturer. No part of a dose should be administered during the 12 hours prior to competing. Do not apply diclofenac cream in combination with any other topical preparations including DMSO, nitrofurazone, or liniments, and do not use on an open wound. Diclofenac cream should not be administered for more than 10 successive days.
3. Whenever phenylbutazone is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 2.0 milligrams per pound of body weight should be administered, preferably less. For a 1000 pound animal, the maximum daily dose is 2.0 grams, which equals two 1.0 gram tablets, or two 1.0 gram units of paste, or 10.0 cc of the injectable (200 milligrams per milliliter). Neither a total daily dose nor part of an injectable dose should be administered during the 12 hours prior to competing. In the event the phenylbutazone is administered orally, half of the maximum daily dose (1.0 grams per 1000 lbs.) can be administered each 12 hours during a five day treatment program. Phenylbutazone should not be administered for more than five successive days.

4. Whenever flunixin meglumine is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 0.5 milligrams per pound of body weight should be administered, preferably less. For a 1000 pound animal, the maximum daily dose is 500 milligrams, which equals two 250 milligram packets of granules, or one 500 milligram packet of granules or 500 milligrams of the oral paste (available in 1500 milligram dose syringes), or 10.0 cc of the injectable (50 milligrams per milliliter). No part of a dose should be administered during the 12 hours prior to competing. Any medicated feed must be consumed and/or removed at least 12 hours prior to competing. Flunixin meglumine should not be administered for more than five successive days.

5. Whenever ketoprofen is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 1.0 milligrams per pound of body weight should be administered, preferably less. For a 1000 pound animal, the maximum daily dose is 1.0 grams, which equals 10.0 cc of the injectable (100 milligrams per milliliter). No part of a dose should be administered during the 12 hours prior to competing. Ketoprofen should not be administered for more than five successive days.

6. Whenever meclofenamic acid is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 12 hours, not more than 0.5 milligrams per pound of body weight should be administered, preferably less. For a 1000 pound animal, the maximum 12 hour dose is 0.5 grams, which equals one 500 milligram packet of granules. Meclofenamic acid should not be administered for more than five successive days.

7. Whenever naproxen is administered, the dose should be accurately calculated according to the actual weight of the animal. Each 24 hours, not more than 4.0 milligrams per pound of body weight should be administered, preferably less. For a 1000 pound animal, the maximum daily dose is 4.0 grams, which equals eight 500 milligram tablets. No part of a dose should be administered during the 12 hours prior to competing. Any medicated feed should be consumed and/or removed at least 12 hours prior to competing. Naproxen should not be administered for more than five successive days.

8. Whenever a permitted NSAID is administered, any additional permitted NSAID must be administered during the 12 hours prior to competing. Only one NSAID may be administered during a 24 hour period.
NSAID should not have been administered during the three (3) days prior to competing.

9. Whenever any NSAID is administered that is not permitted to be used, it should not have been administered during the seven days prior to competing.

Whenever any NSAID is administered to a horse or pony in a manner that might cause the plasma concentration to exceed the quantitative restrictions of the rule (in the case of those permitted to be used), or might cause more than one NSAID to be detected in the animal’s blood or urine sample, or might cause the NSAID to be detected at any concentration in the animal’s blood or urine sample (in the case of those not permitted to be used), the trainer and owner should withdraw the horse or pony from competition, and the animal should be withheld from competition until the plasma concentration of any permitted NSAID returns to acceptable concentrations and/or until any NSAID forbidden at any concentration is no longer present in the animal’s blood or urine sample.

REGARDING METHOCARBAMOL:

1. Whenever methocarbamol is administered, the dose should be accurately calculated according to the actual weight of the horse or pony. Each 24 hours, not more than 5.0 mg per pound of body weight should be administered, preferably less. For a 1000 pound animal, the maximum dose each 24 hours is 5.0 grams, which equals ten 500 milligram tablets or 50 cc of the injectable (100 milligrams per milliliter). No dose should be administered during the 24 hours immediately following the prior dose.

2. No part of a dose should be administered during the 12 hours prior to competing. Any medicated feed must be consumed and/or removed at least 12 hours prior to competing. Methocarbamol should not be administered for more than five successive days.

In any instance methocarbamol has been administered to a horse or pony in a manner that might cause the plasma concentration to exceed the quantitative restriction of the rule, the trainer and owner should withdraw the horse or pony from competition, and the animal should be withheld from competition until the plasma concentration returns to acceptable levels.

ADDITIONAL RESTRICTIONS FOR PARTICULAR CLASSES/DIVISIONS

ANABOLIC STEROIDS

Effective December 1, 2011, anabolic steroids are considered forbidden for all breeds and disciplines competing under USEF Rules. No anabolic steroid is to be administered to a horse or pony in the time before competition such that it, or any metabolite of it, might be present in the animal, or might be detectable in its blood or urine sample at the time of competition. This means that no anabolic steroids should be administered and/or any surgical implants should be removed sufficiently in advance of competing such that these substances are not present in the blood or urine at the time of competition (see HOW LONG DRUGS REMAIN DETECTABLE), and they should not be used thereafter.
HOW LONG DRUGS REMAIN DETECTABLE

The following information about drug detection serves two main purposes. In the context of competing under the USEF’s Prohibited Substance Rule (GR 409) or under FEI Regulations (in the United States) it provides information about how long after the administration of a particular drug it is necessary to refrain from competition in order for the horse to compete in compliance with the rules. In the context of competing under the USEF’s Therapeutic Substance Rule (GR 410-412), it provides information about how long after the administration of a forbidden, therapeutic substance it is necessary to file a Medication Report Form in order for the horse to compete in compliance with the rule. In the case of forbidden, non-therapeutic substances, e.g. fluphenazine and reserpine, it provides information about how long after the administration of such a drug it is necessary to refrain from competition in order for the drug to be no longer detectable in the blood or urine sample of the horse.

The following information is applicable for horses and ponies competing in the United States. It is not applicable to any animal competing outside the United States or under any drug testing program using a laboratory other than the USEF Equine Drug Testing and Research Laboratory.

The FEI may publish alternate detection times for some substances which are to be followed when competing under FEI rules. Please review FEI List of Detection Times at: fei.org/fei/cleansport/ad-h/detection-times

The following information is current at the time of this printing. However, the Federation systematically refines existing drug tests to make them more sensitive, and it develops new tests. Improved testing procedures are routinely implemented at any time without prior notice. Therefore, the time guidelines on the following page might become obsolete as new and more sensitive procedures are implemented. Reliance upon the following guidelines will not serve as a defense to a charge of violation of the rule in the event of a positive drug test.

The following information is applicable to most horses and ponies. Nevertheless, reliance upon it does not guarantee compliance with the rules, since the response of individual horses and ponies may vary. Exhibitors, owners, and trainers should consult the drug manufacturer and knowledgeable veterinarians for up-to-date information and more specific advice concerning the therapeutic use of a drug or medication for a particular horse or pony.

The following information is made available with the assumption that any and all drugs and medications are used only for a therapeutic purpose, i.e., the diagnosis and/or treatment of illness or injury, and that any dose administered is a conservative, therapeutic dose, consistent with the manufacturer’s recommendations. The following guidelines are not part of the rules.

Depending upon the drug administration scenario, e.g., the formulation of the drug, the dose or doses administered, the frequency of administration, the route or routes of administration, the weight of the horse or pony, the health condition of the animal, etc., it is possible that the following substances and their metabolites (by-products) might remain detectable in the blood or urine sample of the animal for a number of days following the final administration of the substance, as follows:
Anabolic steroids:

- boldenone 82 days
- nandrolone 35 days
- stanozolol 47 days
- testosterone 30 days

Long-acting tranquilizers and psychotropics, e.g., fluphenazine and reserpine 90 days

Shorter-acting tranquilizers and sedatives, e.g., acepromazine, detomidine, and xylazine 7 days

Procaine and procaine penicillin 14 days

Local anesthetics other than procaine, e.g., lidocaine and mepivacaine 7 days

Methylprednisolone 14 days

Isoflupredone (intra-articular injection) 7 days

Isoflupredone (sacroiliac injection) 28 days

Corticosteroids other than methylprednisolone and isoflupredone, e.g., triamcinolone and betamethasone 7 days

Nonsteroidal anti-inflammatory drugs, e.g., phenylbutazone and flunixin 3 days

Antihistamines, e.g., cyproheptadine and pyrilamine 7 days

Gabapentin 14 days

Respiratory drugs, e.g., albuterol 7 days

Isoxsuprine 21 days

For guidelines on any other drug or medication, call 800.633.2472.

This information, if heeded, will minimize the chances of positives for forbidden substances; however, all trainers, owners, and exhibitors are cautioned that the foregoing are only general guidelines, and it is the trainer’s responsibility to see to it that conditions prevail for full compliance with all USEF rules.

The requirement to submit, observe, cooperate, and assist

GR402 requires trainers, owners, and their representatives to submit their horses and ponies to the collection of both blood and urine samples, at the discretion of the testing veterinarian appointed by USEF. The animal is to be left in the charge of the testing personnel until all sample collections are completed, or until, in the exclusive discretion of the testing personnel, the animal is released.

In accordance with GR402, trainers are urged to accompany the testing personnel and the animal during the time that samples are collected,
labeled, and sealed, and to serve as witness to these procedures. In the event he or she is unwilling or unable to do so, the trainer is urged to appoint an agent to serve as witness to these procedures. Failure to witness these procedures, and/or failure to appoint an agent to do so, precludes a trainer from subsequently challenging the identity of the horse or pony from which samples were collected, or the procedures employed in collecting, labeling, or sealing the samples.

GR403 requires trainers, owners, and their agents to cooperate with the testing personnel, to take the horse or pony immediately to the location selected by the testing personnel for sample collections, to present the animal for sample collections, to cooperate in the prompt procurement of samples with no unnecessary delays, and to exhibit polite attitude and actions to the testing personnel at all times.

Failure to comply with all of the requirements of GR402 and 403 is a potentially serious violation of the rules that can result in the issuance of charges of a rule violation by the Federation. Those found to have violated these rules can be subject to suspensions, fines, and the revocation of winnings, at the discretion of the Federation’s Hearing Committee.

**CONDITIONS FOR THERAPEUTIC ADMINISTRATIONS OF FORBIDDEN SUBSTANCES**

There are certain conditions under which a forbidden substance might be used in compliance with USEF Equine Drugs and Medications Rules. The complete process and conditions are provided on page 33 of these guidelines under GR411. One step of the process includes filing a Medication Report Form to document compliance with the rule. It is specified that the Equine Drugs and Medications Report Form must be filed with the Steward/Technical Delegate or Designated Competition Office Representative within one hour after administration or one hour after the Steward/Technical Delegate or Designated Competition Office Representative returns to duty if administration is at a time other than during competition hours.

**ELECTRONIC FILING OF EQUINE DRUGS AND MEDICATIONS REPORT FORMS**

To make compliance with GR411 easier to fulfill, the USEF has recently started to accept Medication Report Forms submitted electronically. This form can be submitted at any time prior to competition, but is still under the same time requirements as the paper version. The link to the online version is: usef.org/medicationreportform

**THE VETERINARIAN’S RESPONSIBILITIES**

When dealing with illness or injury in a horse or pony competing at a USEF recognized show or event, the veterinarian should prescribe or administer whatever is indicated for therapeutic purposes. Whenever prescribing or administering a substance forbidden or restricted by the rules, the veterinarian should advise the exhibitor, trainer, and owner how to comply with USEF Rules. However, if the veterinarian (1) fails to give them proper advice, or (2) gives them improper advice about compliance with the rules, or (3) if the trainer, owner, or exhibitor fail to heed the proper advice of the veterinarian, then the trainer and owner may be subject to appropriate penalties under Federation Rules.

No veterinarian should be party to the administration of a drug or medication to a horse or pony for the non-therapeutic purpose of affecting its performance. This
is unethical, and it encourages unethical conduct among trainers, owners, and exhibitors. Such conduct is contrary to USEF Rules, is professionally unethical, and undermines the fairness of competition at horse shows and events.

THE TRAINER’S RESPONSIBILITIES
Under USEF Rules, the trainer is held responsible and accountable for the condition of the horse or pony and for compliance with the rules. The trainer is defined as any adult or adults who has or shares the responsibility for the care, training, custody, condition or performance of the horse or pony. This could be one person or several individuals. Trainers, in the absence of substantial evidence to the contrary, are responsible and accountable under the penalty provisions of these rules, whether or not they have signed an entry blank. They are also responsible for guarding each horse at, and sufficiently prior to a recognized competition, such as to prevent the administration by anyone of or its exposure to any forbidden substance, and to know all the provisions of this rule and all other rules and regulations of the Federation and the penalty provisions of said rules.

For the purposes of this rule, substantial evidence means affirmative evidence of such a clear and definite nature as to establish that the trainer or any employee or agent of the trainer was, in fact, not responsible or accountable for the condition of the horse and/or pony.

Understanding the USEF Equine Drugs and Medications Rule will help avoid inadvertent violations. All questions about the rule should be directed to the USEF Equine Drugs and Medications Program, 956 King Avenue, Columbus, Ohio 43212, toll-free 800.633.2472.

CONCLUSION
One consistent theme which runs through the drug rules of all the private groups is the constant re-evaluation of their positions and the changes made in the rules to accommodate the best thinking of the trainers, owners and veterinarians. As new drugs are developed to treat horses therapeutically and as other drugs are discovered which allow the unscrupulous trainers and veterinarians to take unfair advantage by administering drugs for which there are no effective tests, each association amends its rules to ensure the fairest competition possible for all participants.

CHAPTER 4 DRUGS AND MEDICATIONS
GR401-408. Equine Drugs and Medications Provisions Applicable to All Breeds and/or Disciplines.

GR401
DETERMINING THE EQUINE DRUGS AND MEDICATIONS DESIGNATION FOR EACH BREED OR DISCIPLINE

1. The Board of Directors shall designate every Breed, Discipline, and/or Group competing under Federation Rules as either a Prohibited Substance Group or a Therapeutic Substance Group, as outlined herein below.

2. At each Annual Meeting, each Division Committee shall determine by a majority vote and shall indicate to the Chief Administrator of the Equine Drugs and Medications Program its preference for its Breed or Discipline to be designated as (or to be part of) either a Prohibited Substance Group or a Therapeutic Substance Group. In any instance where more
than one Division Committee is responsible for a Breed and/or Discipline Group, after each committee has determined its preference by a majority vote, unanimity between and/or among the Division Committees of the Group shall be required to invoke a recommendation to be designated a Prohibited Substance Group. Absent such concurrence, the joint recommendation of the Division Committees of the Group shall be construed as a recommendation in favor of designation as a Therapeutic Substance Group.

3. Each Division Committee shall have responsibility to recommend for its division.

4. At its meeting at the Federation’s Annual Meeting, the Equine Drugs and Medications Committee shall take into consideration these recommendations and the written recommendations of the respective Affiliate Associations in this regard, and it shall enact the designation for each Breed, Discipline, and/or Group. The effective dates of these designations shall coincide with the effective dates of the newly published Rule Book.

5. These designations shall be reviewed by each Division Committee at the subsequent Rule Change Convention.

6. Every horse and/or pony competing at Federation competitions and/or events shall be subject to either the Prohibited Substance Provisions (GR409) or the Therapeutic Substance Provisions (GR410-412), depending upon its Breed’s, Discipline’s, and/or Group’s designation, and it shall be required to compete in compliance therewith, whether competing in unrated or rated classes and/or divisions.

7. Any horse and/or pony that competes in more than one Breed, Discipline, and/or Group at a competition, one of which is a Prohibited Substance Group, shall be required to be in compliance with the Prohibited Substance Provisions at all times while competing in any and/or all classes and/or divisions at that competition.

GR402 TESTING

1. Horses and/or ponies competing at a Licensed Competition are subject to examination by a licensed veterinarian who must be appointed by the Administrator of the Equine Drugs and Medications Program. Said appointed veterinarian, with the approval of the Administrator, may appoint a technician to perform certain duties under this Rule. The examination may include physical, urine, blood tests and/or any other test or procedure at the discretion of said veterinarian necessary to effectuate the purposes of this rule. Said veterinarian may examine any or all horses and/or ponies in a class or all classes in a competition or any horses and/or ponies entered in any class, whether in competition or not, if on the competition grounds, or any horse and/or pony withdrawn by any exhibitor within 24 hours prior to a class for which it has been entered.

2. Whether a horse and/or pony is in competition or not, refusal to submit the horse and/or pony for examination or to cooperate with the veterinarian or his agents constitutes a violation and subjects the responsible person to penalties under GR406.
3. Trainers who are not able to accompany Federation drug testing personnel and the horse and/or pony to the location where sample collection is to take place, to act as witness to the collection and sealing of blood and urine samples, and to sign the drug collection documents in the appropriate places as witness, must appoint an agent to do so. The absence of such a witness shall constitute a waiver of any objection to the identification of the horse and/or pony tested and the manner of collection and sealing of the samples.

4. Upon the collection of a sufficient number of tubes of blood from the horse or pony, the tubes shall be divided into two groups. One group shall be labeled and identified as Blood Sample A and the other as Blood Sample B, and they shall be sealed accordingly. Upon the collection of a sufficient volume of urine from the horse or pony, a portion of the sample shall be poured into a second urine sample container. One container shall be labeled and identified as Urine Sample A and the other as Urine Sample B, and they shall be sealed accordingly. These procedures shall be performed whether or not the trainer or his/her appointed witness is present as provided for in Section 3 above.

5. In the event reasonable attempts at sample collections from the horse or pony do not provide a sufficient number of tubes of blood or a sufficient volume of urine to be divided, labeled, and identified as Samples A and B, as determined by the testing veterinarian and/or technician, the sample(s) obtained (if obtained) shall be labeled and identified as Sample(s) A only, and it shall be recorded in the records of the Equine Drugs and Medications Program that the corresponding Sample(s) B does (do) not exist, in which event the obtained Sample(s) shall be subject to testing.

6. A blood sample may be retested under these Rules at any time exclusively at the direction of the Federation. The retesting of a sample may lead to a violation only if the sample was retested within three (3) years from the sample collection date. In order to constitute a violation under these rules, the substance detected in the retested sample must (i) have been forbidden at the time of sample collection; and (ii) not a therapeutic substance, which for purposes of this rule includes only the Controlled Medications on the FEI Prohibited Substances List (available at http://www.fei.org/fei/cleansport) in effect on the sample collection date.

7. In the event that the retested sample proves positive, and the retest was conducted more than one (1) year since the date of collection, no prizes or awards will be required to be returned.

**GR403**

**COOPERATION**

1. Cooperation with the veterinarian and/or his agent(s) includes:

   a. Taking the horse and/or pony and the veterinarian and/or his agent(s) immediately to the location selected by said veterinarian and/or agent(s) for testing the horse and/or pony and presenting it for testing.

   b. Assisting the veterinarian and/or his agent(s) in procuring the sample promptly, including but not limited to removing equipment from the horse and/or pony, leaving it quietly in the stall and avoiding any
distractions to it. Schooling, lengthy cooling out, bandaging and other delays of this type shall be construed as noncooperation.

c. Polite attitude and actions toward the veterinarian and/or his agent(s).

**GR404**

**ACCOUNTABILITY OF TRAINERS AND OTHER PERSONS RESPONSIBLE**

1. Trainers and other Persons Responsible, in the absence of substantial evidence to the contrary, are responsible and accountable under the penalty provisions of these rules. The trainer and other Persons Responsible are not relieved from such responsibility as a result of the lack or insufficiency of stable security.

2. The Persons Responsible may include the individual who rides, vaults, or drives the horse and/or pony during a competition; the Owner; and/or Support Personnel.

3. Support Personnel is defined to include but is not limited to grooms, handlers, longeurs, and veterinarians may be regarded as additional Persons Responsible if they are present at the competition or have made a relevant decision about the horse and/or pony.

4. A trainer is defined as any adult or adults who has or shares the responsibility for the care, training, custody, condition, or performance of a horse and/or pony. Said person must sign the entry blank of any Licensed Competition whether said person be a trainer, owner, rider, agent and/or coach. Where a minor exhibitor has no trainer, then a parent, guardian or agent or representative thereof must sign the entry blank and assume responsibility as trainer. The name of the trainer must be designated as such on the entry blank. It is the responsibility of trainers as well as competition management to see that entry blanks contain all of the required information. The responsibilities of a trainer include, but are not limited to the following:

   a. for the condition of a horse or pony at a Licensed Competition (whether or not they have signed an entry blank),

   b. to guard each horse and/or pony at, and sufficiently prior to, a Licensed Competition such as to prevent the administration by anyone of, or its exposure to, any forbidden substance, and

   c. to know all of the provisions of this Chapter 4 (including any advisories or interpretations published in equestrian) and all other rules and regulations of the Federation and the penalty provisions of said rules. For purposes of this rule, substantial evidence means affirmative evidence of such a clear and definite nature as to establish that said trainer, or any employee or agent of the trainer, was, in fact, not responsible or accountable for the condition of the horse and/or pony. If any trainer is prevented from performing his or her duties, including responsibility for the condition of the horses and/or ponies in his or her care, by illness or other cause, or is absent from any Licensed Competition where horses and/or ponies under his or her care are entered and stabled, he or she must immediately notify the competition secretary and, at the same time, a substitute must be appointed by the trainer and such substitute must place his or her name on the entry
blank forthwith. Such substitution does not relieve the regular trainer of his/her responsibility and accountability under this rule; however, the substitute trainer is equally responsible and accountable for the condition of such horses and/or ponies.

5. The trainer and owner acknowledge that the trainer represents the owner regarding horses and/or ponies being trained or managed, entries, scratches for any reason and any act performed on any horse and/or pony under the care and custody of the trainer.

6. In the case of a horse and/or pony competing under the Therapeutic Substance Provisions, any trainer and/or Persons Responsible subject to these rules who actually administers, attempts to administer, instructs, aids, conspires with another to administer or employs anyone who administers or attempts to administer a forbidden substance to a horse and/or pony which might affect the performance of said horse and/or pony at a competition licensed by the Federation without complying with GR411, is subject to the penalties provided in GR406.

7. Any trainer and/or Persons Responsible subject to these rules who administers, attempts to administer, instructs, aids, conspires with another to administer or employs anyone who administers or attempts to administer any substance to a horse and/or pony by injection or by any other route of administration, whether the substance is forbidden or permitted, in the competition ring of a competition licensed by the Federation during a scheduled class, is subject to the penalties provided in GR406.

GR405
EQUINE DRUGS AND MEDICATIONS TESTING IN CONNECTION WITH AN APPEAL MEASUREMENT

1. Each animal submitted for an appeal measurement is subject to the Drugs and Medications Chapter at the time of said measurement and/or concurrent examinations, and said animal must be in compliance therewith.

2. Each animal submitted for an appeal measurement must have drug testing samples collected at the time of said measurement and/or concurrent examinations. No sample is a drug testing sample unless it is collected by and/or under the direct supervision of Federation drug testing personnel, who must be appointed by the Administrator of the Equine Drugs and Medications Program to collect samples from the animal in question in connection with said measurement.

3. Each animal submitted for an appeal measurement must have both a urine sample and a blood sample collected at the time of said measurement and/or concurrent examinations. Both the urine sample and the blood sample must be of sufficient volume for drug testing purposes, as determined by the Administrator of the Equine Drugs and Medications Program. Said sample collections shall be conducted in accordance with procedures which are the sole prerogative of the Federation drug testing personnel. As deemed necessary by the Federation testing veterinarian, the animal shall be administered furosemide to cause it to produce a urine sample in a timely manner.

4. Every blood sample and/or urine sample collected in connection with an
appeal measurement and all portions thereof are the sole property of the Federation. Said samples and all portions thereof must remain in the sole custody of the Federation drug testing personnel at all times during said measurement and/or concurrent examinations, and subsequently they must be submitted to the Federation's laboratory for testing in accordance with the instructions of the Administrator of the Equine Drugs and Medications Program.

5. The entire cost of sample collections and testing conducted in connection with an appeal measurement, including the fees and expenses of Federation drug testing personnel, shipping costs for equipment and samples, laboratory charges, etc., as determined by the Administrator of the Equine Drugs and Medications Program, must be paid in full by the appellant within 30 days of the submission of an invoice, regardless of the outcome of said measurement, and regardless of the laboratory results. A deposit in cash or certified check equal to the costs of sampling and testing, as estimated by the Administrator of the Equine Drugs and Medications Program, may be required prior to the measurement.

6. No appeal measurement is valid absent written affirmation of the CEO or his designee confirming the receipt of negative drug testing results from the Federation's laboratory, indicating that both the urine and blood sample collected from the animal in question in connection with said measurement and/or concurrent examinations were found to contain no forbidden substance, said results having been issued to the Administrator of the Equine Drugs and Medications Program. Any instance involving a finding of forbidden substance shall additionally result in the issuance of a charge of violation of Chapter 4 for adjudication by the Hearing Committee in accordance with the provisions of Chapters 6 and 7.

**GR406**

**RESULTS, CONFIRMATORY ANALYSIS, AND RETEST**

1. Blood and urine samples labeled and identified as Samples A shall be subjected to chemical analysis by the Federation Drug Testing Laboratory or by a laboratory with which the Federation has contracted for its services. Blood and urine samples labeled and identified as Samples B shall be stored securely, unopened, at the Federation Drug Testing Laboratory, to be used in the event of a confirmatory analysis, or in the event of a future analysis.

2. In the event the chemical analysis of Blood or Urine Sample A is negative, i.e., no forbidden substance or any metabolite or analogue thereof is found to be present in the sample, the corresponding Blood or Urine Sample B may be frozen and maintained, at the Federation Equine Drug Testing and Research Laboratory, for possible future chemical analysis.

3. In the event the chemical analysis of Blood or Urine Sample A is positive, i.e., a forbidden substance or any metabolite or analogue thereof is found to be present in the sample, this shall be prima facie evidence that the forbidden substance was administered in some manner to said horse or pony, whether intentionally or unintentionally, or otherwise was caused to be present in the tissues, body fluids or excreta of the horse or pony at the competition, whether intentionally or unintentionally, such that the trainer(s) deemed responsible and accountable for its condition is (are)
liable under the provisions of GR404.

4. In the event the chemical analysis of Blood or Urine Sample A is positive, the Federation shall notify the Trainer, Persons Responsible (if applicable), and the Owner of the Horse of their right to promptly request the analysis of the B sample, or, failing such request, that the B sample analysis is deemed waived. The Trainer, Persons Responsible (if applicable), and the Owner of the Horse are deemed to have waived their right to a B Sample analysis if they do not submit the Confirmatory Analysis Request Form within 15 business days. Within seven (7) days of receipt of the duly executed Confirmatory Analysis Request Form (B Sample), the Federation shall coordinate such analysis. The Trainer, Persons Responsible (if applicable), and Owner of the Horse may accept the A Sample analytical results by waiving the right to a B sample analysis.

5. The confirmatory analysis of the corresponding Blood or Urine Sample B shall be performed by a drug testing laboratory that is approved by the Federation and agreed upon by the person charged who requests the confirmatory analysis, which laboratory must have demonstrated proficiency in performing the necessary confirmatory analysis, provided the corresponding Blood or Urine Sample B exists and is of sufficient volume to permit a confirmatory analysis. In the event the drug testing laboratory that analyzed Sample A is the only laboratory that has demonstrated proficiency in performing the necessary confirmatory analysis, this laboratory shall be the only laboratory to perform the confirmatory analysis of the corresponding Sample B. Upon the completion of the confirmatory analysis, the laboratory performing the confirmatory analysis shall forward its findings and supporting data to all parties.

6. In the event no agreement is reached as to a laboratory as required in section 5 above, and the person charged who requests the confirmatory analysis does not revoke his/her request, the confirmatory analysis of the corresponding Blood or Urine Sample B shall be performed by the Federation Drug Testing Laboratory, or by a laboratory with which the Federation has contracted for its services, and shall forward its findings and supporting data to all parties. Both the results of the analysis of Sample A (and supporting data) and the results of the confirmatory analysis of the corresponding Sample B, if any (and supporting data, if any), shall be admissible as evidence in any hearing or proceeding pertaining to this matter.

7. In the event the corresponding Blood or Urine Sample B does not exist, or is of insufficient volume to permit a confirmatory analysis, and there exists a remaining aliquot of Blood or Urine Sample A which is of sufficient volume to permit a retest, as determined by the Federation, a person charged who requests the retest of Blood or Urine Sample A must make the request in writing to the Federation and it must be received within 7 days of the determination that the corresponding Blood or Urine Sample B does not exist or is of insufficient volume to permit a confirmatory analysis.

8. Any requested re-test of the remaining aliquot of Blood or Urine Sample A, provided it is of sufficient volume to permit a retest, shall be performed by the Federation Drug Testing Laboratory, or by a laboratory with which The Federation has contracted for its services.
9. The retest of the remaining aliquot of Blood or Urine Sample A may be witnessed by a Witnessing Analyst appointed by the person charged who requests such analysis at the same time as the retest is requested. The Witnessing Analyst must be a qualified analytical chemist employed by an equine drug testing laboratory. If no Witnessing Analyst is appointed by the person requesting the retest, or if the Witnessing Analyst is unavailable within a reasonable time, the requested retest of the remaining aliquot of Blood or Urine Sample A shall proceed without the Witnessing Analyst.

10. In the event the Witnessing Analyst appointed by the person requesting the retest of the remaining aliquot of Blood or Urine Sample A is satisfied that the positive result is correct, the Federation must be informed immediately by fax with confirmation by letter.

11. In the event the Witnessing Analyst is not satisfied that the result of the retest of the remaining aliquot of Blood or Urine Sample A is correct, the Federation must be informed immediately by fax followed by a written report setting forth the basis for the Witnessing Analyst's opinion. Copies of the original and subsequent results and supporting analytical data must be submitted to the Federation Hearing Committee as part of the hearing record in the case, for resolution by it of any and all issues regarding the original analysis of Blood or Urine Sample A and the retest of the remaining aliquot of Blood or Urine Sample A.

12. By requesting the confirmatory analysis of the corresponding Blood or Urine Sample B, or the retest of the remaining aliquot of Blood or Urine Sample A, or by requesting that the retest be witnessed by a Witnessing Analyst, the person charged who makes such request(s) agrees to and must pay any and all fees, costs and expenses relating to the confirmatory analysis or the retest, whether it is performed by a mutually agreed upon laboratory, by the Federation Drug Testing Laboratory, or by a laboratory with which The Federation has contracted for its services, upon the presentation an invoice by the Federation, and any and all fees, costs, and expenses relating to the Witnessing Analyst.

13. After chemical analysis of the B sample, if the laboratory's confirmatory analysis:

   Does not substantially confirm the Federation Equine Drug Testing and Research Laboratory's findings, then any allegations that the substance in question was present at the time that the samples were collected shall be dismissed; or

   Substantially confirms the Federation Equine Drug Testing and Research Laboratory's findings, the finding shall be considered conclusive.

14. In the case of a horse and/or pony competing under the Therapeutic Substance Provisions, if the chemical analysis of the sample taken from such horse and/or pony indicates the presence of a forbidden substance or any metabolite or analogue thereof and all the requirements of GR411 have been fully complied with, the information contained in said Equine Drugs and Medications Report Form and any other relevant evidence will be considered by the Federation in determining whether a rule violation was committed by any person(s) responsible or accountable for the
condition of the horse and/or pony under the provisions of this rule.

15. When a positive report is received from the chemist identifying a forbidden substance, or any metabolite or analogue thereof, a hearing will be held in accordance with Chapter 6, except as may otherwise be provided by GR412. No trainer, responsible or accountable for the condition of said horse and/or pony, will be suspended, or a horse and/or pony barred from competition, until after an administrative penalty has been assessed or after the conclusion of a hearing and a written ruling thereon has been made.

16. The owner or owners of a horse and/or pony found to contain a forbidden substance or any metabolite or analogue thereof may be required to forfeit all prize money, sweepstakes, added money and any trophies, ribbons and “points” won at said competition by said horse and/or pony and the same will be redistributed accordingly. The owner must pay a fee of $300 to said competition. Points accumulated toward Horse of the Year Awards prior to said competition may be nullified and redistributed at the discretion of the Hearing Committee. If, prior to or at a hearing, the Federation as the charging party, determines that one or more persons, not previously charged as a trainer should also be charged as a trainer, then, upon application by the Federation, the Hearing Committee may, in its discretion, continue or adjourn the hearing, in whole or in part, to permit a new or amended charge to be issued (unless the person(s) to be charged waive notice).

17. A trainer of a horse and/or pony found to contain such forbidden substance or any metabolite or analogue thereof is subject to whatever penalty is assessed by the Hearing Committee, except for administrative penalties issued by the Chairman of the Equine Drugs and Medications Committee and accepted, as provided by GR412. Said trainer may be fined and may be suspended from all participation in Licensed Competitions for a period of one year for the first offense, and for a longer period for a second or later offense, said suspension to be served at any time at the discretion of the Hearing Committee.

The horse and/or pony may be suspended for any period of time specified by the Hearing Committee. In determining an appropriate penalty under these rules, the Hearing Committee may take into account such factors and circumstances as it may deem relevant, including but not limited to the pharmacology of the forbidden substance,

the credibility and good faith of the person charged or of other witnesses,

penalties determined in similar cases, and

past violations of any Federation rules (or the lack thereof).

reliance upon the professional ability or advice of a veterinarian who is a licensed graduate of an accredited veterinary school and who is in good standing in the state in which he/she primarily practices.

18. If the Hearing Committee determines that any violation or attempted violation of this Rule was willful and/or intentional, there shall not be any limit to the period of a suspension, and the Hearing Committee may
impose other and significantly greater penalties than it would have in the absence of such a determination.

19. A blood sample may be retested under these Rules at any time exclusively at the direction of the Federation. The retesting of a sample may lead to a violation only if the sample was retested within three (3) years from the sample collection date. In order to constitute a violation under these rules, the substance detected in the retested sample must (i) have been forbidden at the time of sample collection; and (ii) not a therapeutic substance, which for purposes of this rule includes only the Controlled Medications on the FEI Prohibited Substances List (available at http://www.fei.org/fei/cleansport) in effect on the sample collection date.

20. In the event that the retested sample proves positive, and the retest was conducted more than one (1) year since the date of collection, no prizes or awards will be required to be returned. BOD 6/20/16 Effective 7/1/16.

GR407 MANAGEMENT PROCEDURES

1. To provide funds for research, inspection and enforcement of rules regarding use of medications and drugs, each Licensed Competition, except where prohibited by law, must assess the exhibitors a fee of $8 for each horse and/or pony entered in the competition, except the fee shall be $20 for each horse entered in an FEI sanctioned competition or a USEF High Cap Computer List Class. Participants in the following classes are exempted from payment:
   a. leadline
   b. exhibitions
   c. games and races,
   d. classes for 4-H members,
   e. Academy classes (Academy classes are classes limited to horses used regularly in a lesson program)
   f. Opportunity classes
   g. Classes at Regular or Local Competitions restricted to breeds or disciplines whose rules are not included in the USEF rulebook.
   h. However, these classes are not exempt from the Drugs and Medications Chapter itself. Within 10 days after a competition, competition management must forward to the Federation a sum representing the above fee times the number of horses and/or ponies entered in the nonexempt classes of the competition plus the number of horses and/or ponies scratched where the fee is not refunded, such sum to be held by the Federation in a separate fund for use to accomplish the purpose set forth above.

2. It is a violation for a Licensee to assess and/or collect a drug enforcement fee in excess of or in addition to that specified and required by GR407.1 of these rules, unless said assessment is approved in writing by the Federation in advance, and then only under the terms and conditions set forth.

3. It is a violation for a Licensee to withhold from the Federation any or all of the drug fees collected in accordance with GR407.1, for any purpose,
including to defray the expenses incurred providing stalls, passes, and other items to the Federation drug testing personnel, as required by GR407.4 and .5.

4. Each Licensed Competition shall, at its own cost and expense, set aside and make available to The Federation testing personnel upon request suitable facilities conveniently located for the veterinarian appointed by the Federation and his or her technicians to collect equine blood and urine samples. Suitable facilities means one or more stalls if available, as requested, that are well lit, clean, dry, freshly bedded, and having a door or gate that can be secured.

5. Each Licensed Competition, upon request, must furnish the veterinarian appointed by The Federation and/or the Administrator of the Equine Drugs and Medications Program by mail forthwith, with the requested number of official passes and parking passes for the veterinarians and technicians to have immediate and free access to all areas at said Licensed Competition.

6. Competition management must cooperate with and exhibit polite attitude and actions toward the veterinarian and/or his agents.

GR408
INTERPRETATIONS OF THE FEDERATION EQUINE DRUGS AND MEDICATIONS CHAPTER AND ITS APPLICATION TO PARTICULAR SUBSTANCES

Any questions regarding the interpretation of this Chapter, including the application of this Chapter to particular substances, should be directed to the office of the Federation Equine Drugs and Medications Program, 956 King Avenue, Columbus, Ohio 43212-2655. (800) 633-2472, (614) 299-7707, FAX (614) 299-7706. Trainers and/or owners who seek advice concerning the interpretation and application of this rule should not rely solely upon interpretations or advice by private or competition veterinarians, competition officials, competition personnel, or other persons, but should also obtain verification of any such interpretations or advice from the Federation Equine Drugs and Medications Program office. Any trainer or owner who is uncertain about whether this rule applies in any given situation would be well advised to withdraw the affected horse and/or pony from competition until such time as the Federation Equine Drugs and Medications Program office has been consulted.

GR409
EQUINE DRUGS AND MEDICATIONS, PROHIBITED SUBSTANCE PROVISIONS

1. This paragraph applies only to FEI Banned Substances and Methods.

For all Federation Equestre Internationale (FEI) recognized disciplines, Articles 2 (what constitutes a violation), 3 (proof of violations (except 3.1 and 3.2.3)), 4 (banned substances and methods), and 8.2 (principles of fair hearing) of the FEI Equine Anti-Doping rules govern. Those Articles are incorporated by reference as if fully set out herein and can be found at www.fei.org or the Drugs & Medications tab at www.usef.org. For purposes of this rule, the designation of “Person Responsible” in the incorporated provisions of the FEI Equine Anti-Doping rules shall refer to the individual(s) found to be the trainer of the horse as defined by GR404.
2. No horse and/or pony competing in a Breed or Discipline designated as (or part of) a Prohibited Substance Group is to be shown in any class at a competition licensed by the Federation if it has been administered in any manner or otherwise contained in its tissues, body fluids or excreta a prohibited substance as defined in the FEI Equine Anti-Doping and Controlled Medication Regulations, which can be found at www.fei.org.

3. EXHIBITORS, OWNERS, TRAINERS, AND VETERINARIANS ARE CAUTIONED AGAINST THE USE OF MEDICINAL PREPARATIONS, TONICS, PASTES, AND PRODUCTS OF ANY KIND, THE INGREDIENTS AND QUANTITATIVE ANALYSIS OF WHICH ARE NOT SPECIFICALLY KNOWN, AS MANY OF THEM NO DOUBT CONTAIN ONE OR MORE FORBIDDEN SUBSTANCES.

**GR410 EQUINE DRUGS AND MEDICATIONS, THE THERAPEUTIC SUBSTANCE PROVISIONS**

1. No horse and/or pony competing in a Breed or Discipline designated as (or part of) a Therapeutic Substance Group is to be shown in any class at a competition licensed by the Federation (see also GR402.1, last sentence) if it has been administered in any manner or otherwise contains in its tissues, body fluids or excreta a forbidden substance except as provided in GR411. Any horse and/or pony that competes in more than one Breed, Discipline, and/or Group at a competition, one of which is a Prohibited Substance Group, shall be required to be in compliance with the Prohibited Substance Provisions at all times while competing in any and/or all classes and/or divisions at that competition. For purposes of this rule, a forbidden substance is:

   a. Any stimulant, depressant, tranquilizer, local anesthetic, psychotropic (mood and/or behavior altering) substance, or drug which might affect the performance of a horse and/or pony (stimulants and/or depressants are defined as substances which stimulate or depress the cardiovascular, respiratory or central nervous systems), or any metabolite and/or analogue of any such substance or drug, except as expressly permitted by this rule.

   b. Any corticosteroid present in the plasma of the horse/pony other than dexamethasone (see GR410.5b).

   c. Any nonsteroidal anti-inflammatory drug in excess of one present in the plasma or urine of the horse/pony (GR411 does not apply); exception: salicylic acid.

   d. Any substance (or metabolite and/or analogue thereof) permitted by this rule in excess of the maximum limit or other restrictions prescribed herein.

   e. Any substance (or metabolite and/or analogue thereof), regardless of how harmless or innocuous it might be, which might interfere with the detection of any of the substances defined in (a), (b), (c) or (e) or quantification of substances permitted by this rule.

   f. Any anabolic steroid (GR411 below does not apply).

2. EXHIBITORS, OWNERS, TRAINERS, AND VETERINARIANS ARE CAUTIONED AGAINST THE USE OF MEDICINAL PREPARATIONS, TONICS, PASTES, AND PRODUCTS OF ANY KIND, THE INGREDIENTS AND QUANTITATIVE ANALYSIS OF WHICH ARE NOT SPECIFICALLY KNOWN, AS MANY OF THEM MAY
3. The full use of modern therapeutic measures for the improvement and protection of the health of the horse and/or pony is permitted unless:

   a. The substance administered is a stimulant, depressant, tranquilizer, local anesthetic, drug or drug metabolite which might affect the performance of a horse and/or pony or might interfere with the detection of forbidden substances or quantification of permitted substances; or
   
   b. More than one nonsteroidal anti-inflammatory drugs are present in the plasma or urine of the horse/pony (GR411 does not apply); exception: salicylic acid; or
   
   c. The presence of such substance in the blood or urine sample exceeds the maximum limit or other restrictions prescribed herein below.

4. Restrictions concerning the nonsteroidal anti-inflammatory drugs are as follows:

   a. The maximum permitted plasma concentration of diclofenac is 0.005 micrograms per milliliter.
   
   b. The maximum permitted plasma concentration of phenylbutazone is 15.0 micrograms per milliliter.
   
   c. The maximum permitted plasma concentration of flunixin is 1.0 micrograms per milliliter.
   
   d. The maximum permitted plasma concentration of ketoprofen is 40.0 nanograms per milliliter.
   
   e. The maximum permitted plasma concentration of meclofenamic acid is 2.5 micrograms per milliliter.
   
   f. The maximum permitted plasma concentration of naproxen is 40.0 micrograms per milliliter.
   
   g. Not more than one of the substances listed in (a) through (g) are permitted to be present in the same plasma or urine sample (GR411 does not apply).
   
   h. The maximum permitted plasma concentration of firocoxib is 0.240 micrograms per milliliter.
   
   i. Any nonsteroidal anti-inflammatory drug not listed in (a) through (g) above is forbidden to be present in the plasma or urine sample (GR411 does not apply); exception: salicylic acid.
   
   j. Any nonsteroidal anti-inflammatory drug that becomes approved for use in horses can be added to the list of those permitted, after the completion, review and approval of the needed research.

5. Restrictions concerning other therapeutic substances are as follows:

   a. The maximum permissible plasma concentration of methocarbamol is 0.5 micrograms per milliliter.
   
   b. The maximum permitted plasma concentration of dexamethasone is 0.5 nanograms per milliliter.

6. Thresholds for substances of possible dietary origin are as follows:
a. The maximum permissible urine concentration of theobromine is 2.0 micrograms per milliliter.

7. Additional restrictions concerning particular classes and/or divisions (GR411 does not apply):

a. In the breeding/in-hand classes for three-year-olds and under in the Arabian, Half Arabian, and Anglo Arabian Division, any anabolic steroid is forbidden. (See HOW LONG DRUGS REMAIN DETECTABLE in the current Drugs and Medications Rules Pamphlet for guidelines).

GR411
CONDITIONS FOR THERAPEUTIC ADMINISTRATIONS OF FORBIDDEN SUBSTANCES

1. A horse and/or pony exhibiting at a Licensed Competition pursuant to the Therapeutic Substance Provisions that receives any medication which contains a forbidden substance is not eligible for competition unless all of the following requirements have been met and the facts are furnished in writing on a timely-submitted official Equine Drugs and Medications Report Form:

   a. The medication must be therapeutic and necessary for the diagnosis or treatment of an existing illness or injury. Administration of a forbidden substance for non-therapeutic or optional purposes (such as, by way of example only, shipping, clipping, training, turning out, routine floating or cleaning of teeth, non-diagnostic nerve blocking, uncasting, mane pulling or non-emergency shoeing) is not considered to be therapeutic. Any trainer who is uncertain about whether a particular purpose is considered to be therapeutic would be well advised to consult the Federation Equine Drugs and Medications Program office.

   b. The horse and/or pony must be withdrawn from competition for a period of not less than 24 hours after the medication is administered.

   c. The medication must be administered by a licensed veterinarian, or, if a veterinarian is unavailable, only by the trainer pursuant to the advice and direction of a veterinarian.

   d. Identification of medication—the amount, strength and mode of administration.

   e. Date and time of administration.

   f. Identification of horse and/or pony, its name, age, sex, color and entry number.

   g. Diagnosis and reason for administration.

   h. Statement signed by person administering medication.

   i. Equine Drugs and Medications Report Form filed with the Steward/Technical Delegate or Designated Competition Office Representative within one hour after administration or one hour after the Steward/Technical Delegate or Designated Competition Office Representative returns to duty if administration is at a time other than during competition hours.

   j. The Steward, Technical Delegate, or Designated Competition Office Representative must sign and record the time of receipt on the Equine Drugs and Medications Report Form.

   k. At selection trials for World Championships, and/or Olympic and/or
Pan American Games, the requirement of subsection (b) above, that the horse or pony must be withdrawn from competition for a period of not less than 24 hours after the medication is administered will not apply, provided that:

1. the competition is conducted pursuant to the written selection procedures as approved by the Federation Board of Directors;

2. the written selection procedures specifically allow for therapeutic administrations of medications by a USEF-appointed veterinary panel within 24 hours preceding competition, and the written selection procedures are in no case less stringent in this regard than the FEI Veterinary Regulations (Articles 1006.7 and 1006.8) and guidelines pursuant thereto;

3. all requirements of the written selection procedures regarding therapeutic administrations of medications have been met;

4. all requirements of this Rule have been met except subsection GR411.1(b); and all persons competing in the competition are eligible and competing for selection.

2. Where all the requirements of GR411 have been fully complied with, the information contained in said Equine Drugs and Medications Report Form and any other relevant evidence will be considered by the Federation in determining whether a rule violation was committed by any person(s) responsible or accountable for the condition of the horse and/or pony under the provisions of this rule.

NOTE: The official Equine Drugs and Medications Report Form is available from the officiating Steward/Technical Delegate and/or Competition Secretary. All required information must be included when filing a report. Failure to satisfy and follow all the requirements of this Rule and to supply all of the information required by such Equine Drugs and Medications Report Form is a violation of the rules. The Steward/Technical Delegate must report any known violations of this Rule to the Federation for such further action as may be deemed appropriate.

3. Flunixin, in addition to one other substance listed in GR410 (a) through (g), may be found in the same plasma and/or urine sample of a horse under the following conditions and for the treatment of colic or an ophthalmic emergency only: (i) must comply with GR411.1; (ii) the flunixin must have been administered by a veterinarian; (iii) the required medication report form must be signed by the administering veterinarian; and (iv) the horse must be withdrawn from competition for 24 hours following the administration.

GR412

ADMINISTRATIVE PENALTIES

1. The provisions for administrative penalties shall apply to any potential or alleged violation of the Equine Drugs and Medications Rule. The Federation shall hold in abeyance the issuance of charges of rule violation pending further determination by the Chairman of the Equine Drugs and Medications Committee, who shall take into consideration all pertinent information available, including the seriousness of the alleged violation(s), precedents in similar Federation drug cases, and any prior rule violation(s) by the individual(s). At all times while consideration is
given as to a determination by the Chairman of the Equine Drugs and Medications Committee, the identity of the horse, rider, trainer, coach, and owner must not be known or disclosed to him.

2. The Chairman of the Equine Drugs and Medications Committee shall, upon consultation with staff, and within 60 days of receipt of laboratory results, make a determination in his or her discretion whether to recommend the issuance of charges by the Federation, whether to recommend a plea agreement, whether to impose administrative penalties, or whether to take no further action in the matter, and shall communicate that decision in writing to the Federation’s CEO or his designee.

3. In the event the Chairman of the Equine Drugs and Medications Committee determines to impose administrative penalties in accordance with GR412.2, in lieu of a recommendation to issue charges, he or she shall be authorized to impose any or all of the penalties enumerated in Chapter 7, GR703, setting forth the terms and conditions for compliance. The trainer(s) and owner(s) shall after receiving written notice of the right to a hearing, after their written waiver of same, and written acceptance of an administrative penalty, be subject to any and all administrative penalties imposed by the Chairman of the Equine Drugs and Medications Committee.

4. The Federation shall give written notification to trainer(s) and owner(s) of administrative penalties determined pursuant to GR412.3 above, the terms and conditions of which shall not be subject to negotiation. An administrative penalty must be approved by the Hearing Committee Co-Chairs before it is offered to the Respondent(s). Once accepted by all parties and by the Hearing Committee, an administrative penalty shall have the same force and effect as would a finding of rule violation by the Hearing Committee following a hearing pursuant to Chapters 6 and 7, and will be published on the Federation’s web site.

5. Any trainer(s), or owner(s), or both, who have received notice of an administrative penalty under GR412.4 and who have not accepted same in writing shall receive a hearing before the Hearing Committee, in accordance with Chapters 6 and 7. Administrative penalties accepted in accordance with this Rule shall be effective immediately, shall be final, and shall not be subject to further review under any circumstance(s).

6. In the event an administrative penalty is not accepted in writing, the Federation shall issue a written charge or charges pursuant to Chapter 6, and the Hearing Committee shall conduct a hearing pursuant to Chapters 6 and 7 upon said charge(s). In the event of a finding of a violation, the Hearing Committee shall not be limited in choice of penalties to those that might have been imposed in accordance with GR412.2 and .3, nor in any such instance shall the Hearing Committee be limited in any other way in exercising all of its prerogatives as set forth in the Bylaws and Rules.

7. A blood sample may be retested under these Rules at any time exclusively at the direction of the Federation. The retesting of a sample may lead to a violation only if the sample was retested within three (3) years from the sample collection date. In order to constitute a violation under these rules, the substance detected in the retested sample must (i) have been forbidden at the time of sample collection; and (ii) not a therapeutic
substance, which for purposes of this rule includes only the Controlled Medications on the FEI Prohibited Substances List (available at http://www.fei.org/fei/cleansport) in effect on the sample collection date.

8. In the event that the retested sample proves positive, and the retest was conducted more than one (1) year since the date of collection, no prizes or awards will be required to be returned.

GR 413
HUMAN DRUG TESTING

1. In accordance with the rules of the FEI and of the World Anti-Doping Agency (WADA), any Federation member shall comply with in-competition, no advance notice (NAN), and other out-of-competition drug testing conducted by the FEI, WADA, US “Anti-Doping Agency (USADA) or by a WADA-authorized organization or USADA-authorized organization at any time without advanced notice. Failure to cooperate with such in-competition, NAN or other out-of-competition drug testing shall be a violation of Federation rules.

2. In conjunction with the above-described NAN or other out-of-competition drug testing, the Federation is required to submit the names, current addresses, telephone numbers, training times and training and competition locations for individuals and teams as requested by the FEI, WADA, or USADA to enable FEI, WADA, or USADA to conduct NAN or other out-of-competition drug testing. Notwithstanding the foregoing, compliance with anti-doping regulations rests with the individual subject to testing.

3. A finding of violation of human drug rules by USADA or WADA shall be deemed a violation of Federation rules, and the reciprocity provisions of GR615.2 shall be applied.

GR 414
PROHIBITED PRACTICES

1. No injectable substances may be administered to any horse or pony within 12 hours prior to competing, with the following three exceptions subject to paragraph 2 below:

a. Therapeutic fluids, which amount must consist of a minimum of 1L of polyionic fluids per 100lb of body weight; and which must be used in accordance with the manufacturer’s recommendations and guidelines. The fluids must not be supplemented with concentrated electrolytes, such as magnesium.

b. Antibiotics. Procaine penicillin G is prohibited under this exception.

c. Dexamethasone. This is permitted only for the treatment of acute urticaria—(hives). The dose must not exceed 0.5 mg per 100 lb (5.0 mg for 1000 lb horse) if administered more than 6 hours and less than 12 hours prior to entering the competition ring, and must not exceed 1.0 mg per 100 lb (10.0 mg for 1000lb horse) within any 24 hour period.

2. The above exceptions are permitted only when (i) the substance is administered by a licensed veterinarian and no less than 6 hours prior to competing; and (ii) the “Trainer” as defined under General...
Rule 404 properly files, or causes to be properly filed, an Equine Drugs and Medications Report Form with the Steward/Technical Delegate or competition office representative within one hour after the administration of the substance or one hour after the Steward/Technical Delegate or competition office representative returns to duty if the administration occurs at a time outside competition hours. The Steward/Technical Delegate or competition office representative shall sign and record the time of receipt on the Equine Drugs and Medications Report Form.

3. No horse may be injected with any substance, forbidden or permitted, into an intra-synovial space (joint, tendon sheath, or bursa) within the 4 days preceding competition. No horse less than two years of age may be treated with intrasynovial injections within the 30 days preceding competition.

4. Shockwave Therapy may only be administered by or on the order of a licensed veterinarian. If sedation is required for Shockwave Therapy, only sedation performed by a licensed veterinarian and administered at the same time as the Shockwave Therapy will be considered therapeutic and GR411 will apply. No sedation associated with Shockwave Therapy will be considered therapeutic if administered within 24 hours prior to competition. No horse may be treated with Shockwave Therapy within the 3 days preceding competition with the following exception:

a. Shockwave Therapy may be administered by a licensed veterinarian within the 3 day prohibited period, but no closer than 12 hours prior to competing, and is limited to application to the back and dorsal pelvis areas. No Shockwave Therapy is permitted within the 12 hours prior to competing. This exception is permitted only when the “Trainer” as defined under GR404 properly files, or causes to be properly filed, an Equine Drugs and Medications Report Form with the Steward/Technical Delegate or competition office representative within one hour after the administration of Shockwave Therapy or one hour after the Steward/Technical Delegate or competition office representative returns to duty if the administration occurs at a time outside competition hours. The Steward/Technical Delegate or competition office representative shall sign and record the time of receipt on the Equine Drugs and Medications Report Form.